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ABSTRACT
Background: Patent ductus arteriosus (PDA) is a relatively 
common congenital heart disease and the alternatives for the 
treatment of PDA > 2.5 mm are surgery or percutaneous oc-
clusion with plugs. The latter, although considered the method 
of choice, are not provided by the Brazilian National Health 
System (Sistema Único de Saúde – SUS). Our objective was to 
compare the incremental cost-effectiveness ratio (ICER) of both 
strategies. Methods: Systematic review of clinical outcomes 
and development of a decision-making algorithm to evaluate 
the ICER of Amplatzer™ Duct Occluder (ADO) vs. surgical 
treatment for the closure of PDA. Costs for both methods were 
calculated based on the reimbursement figures paid by the 
SUS in 2010 and the cost of the percutaneous kit (device + 
support materials) was estimated at R$ 10,000.00. We used 
as a threshold the willingness to pay the equivalent of three 
times the Brazilian Gross Domestic Product, i.e., R$ 57,000.00 
per year of life saved. Results: Both techniques were safe 
and effective with less morbidity and shorter hospitalization 
time for percutaneous closure. Adjusted life expectancy was 
similar in both groups, and slightly better for the ADO group. 
Total cost was calculated as R$ 8,507 for surgery and R$ 
11,000.00 for ADO. ICER was calculated as R$ 71,380.00 per 
year of life saved. A threshold analysis showed that a reduc-
tion of R$ 492.65 in the cost of the ADO kit would reduce 
the ICER to an acceptable value for the incorporation of this 
technology by the SUS. Conclusions: Percutaneous occlusion 
was associated with less morbidity and shorter hospital stay 
with similar incremental effectiveness when compared to the 
surgical treatment. With the direct costs used in this study 
and considering that the entire population with PDA is treated 
with the ADO, percutaneous occlusion was less cost-effective. 
However, a slight reduction in the costs of the percutaneous 
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RESUMO
Custo-Efetividade Incremental do Tratamento 
Cirúrgico vs. Percutâneo da Persistência do Canal 
Arterial com o Amplatzer® Duct Occluder em 
Crianças: Revisão Sistemática
Introdução: A persistência do canal arterial (PCA) é uma car-
diopatia congênita relativamente comum e as alternativas para 
o tratamento de canais > 2,5 mm são a cirurgia ou a oclusão 
percutânea com próteses do tipo rolha. Essas últimas, apesar 
de consideradas o método de escolha, não estão previstas pelo 
Sistema Único de Saúde (SUS). Nosso objetivo foi comparar 
a razão de custo-efetividade incremental (RCEI) de ambas as 
estratégias. Métodos: Revisão sistemática em relação a desfechos 
clínicos e criação de modelo de decisão para avaliação da 
RCEI do Amplatzer® Duct Occluder (ADO) em comparação ao 
tratamento cirúrgico, para o fechamento da PCA. Os custos para 
ambos os métodos foram aqueles reembolsados pelo SUS em 
2010, e o custo do conjunto (dispositivo + materiais de apoio) 
foi estimado em R$ 10.000,00. Foi considerado como limiar 
uma disposição para pagar equivalente a três vezes o Produto 
Interno Bruto brasileiro, resultando em R$ 57.000,00 por ano 
de vida salvo. Resultados: As duas técnicas foram seguras e 
eficazes, com menor morbidade e tempo de internação no 
fechamento percutâneo. A expectativa de vida ajustada foi 
similar nos dois grupos, sendo um pouco melhor para o ADO. 
O custo total foi calculado em R$ 8.507,00 para cirurgia e 
em R$ 11.000,00 para o ADO. A RCEI foi calculada em R$ 
71.380,00 por ano de vida ganho. Uma análise de limiar 
demonstrou que a redução do valor do conjunto completo 
do ADO em R$ 492,65 traria a RCEI para o limiar aceitável 
para incorporação ao SUS nos dias de hoje. Conclusões: O 
tratamento percutâneo apresentou morbidade e tempo de 
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kit would result in a acceptable ICER threshold for possible 
incorporation by the SUS.
 
 
 
 
DESCRIPTORS: Ductus arteriosus, patent. Heart defects, con-
genital. Surgery. Prostheses and implants. Cost-benefit analysis.
over 5 kg, adolescents, and adults, percutaneous clo-
sure is usually the most appropriate option, due to its 
high efficiency, very low morbidity (less than surgery), 
and limited hospitalization time.5 Spring-like prostheses 
(coils) are employed in smaller channels (<  2.5 mm), 
and channels with constriction in the pulmonary side 
(Krichenko type A, D, and E).6 Plug-type prostheses are 
indicated for major, window-type (B), or tubular-type 
(C) channels.
Several Brazilian groups have been performing 
percutaneous closure of PDA with various types of 
devices in patients with supplementary health insurance 
plans and in those included in research protocols, with 
excellent results.4,7-10 Taking in consideration that, in 
the Brazilian Unified Health System (Sistema Único de 
Saúde – SUS), only coils are approved for clinical use, 
the percutaneous closure of major channels is unviable, 
requiring a surgical solution. The main factor that limits 
the incorporation of this technology by the SUS is the 
value of the prostheses. Conversely, it is speculated that 
the higher morbidity and the longer in-hospital length 
of stay for surgery patients3 may financially burden the 
hospital system, due to the higher occupancy rate of 
beds and of the operating room, and also due to the 
treatment of possible complications.
To date, no Brazilian studies taking into account the 
costs were published, when comparing both methods of 
PDA treatment. Thus, the present study aimed to conduct 
an economic analysis of incremental cost-effectiveness, 
in order to compare surgical versus percutaneous closure 
of this common congenital heart defect in conditions 
amenable to the use of both strategies, through the 
perspective of the SUS.
METHODS
Systematic revision
Search strategy and bibliographic databases
This systematic review used MEDLINE and the 
Cochrane Central bibliographic databases, accessed 
on PubMed and Wiley Library Online portals, re-
spectively. The search strategy on PubMed included 
terms referring to PDA, interventions (surgical and 
internação menores, além de efetividade incremental semel-
hante àquela do tratamento cirúrgico. Com os valores diretos 
estipulados neste estudo e partindo do pressuposto de que 
toda a população de pacientes com PCA seria tratada com 
o ADO, o fechamento percutâneo foi menos custo-efetivo. 
Entretanto, com pequena redução nos valores do conjunto, o 
procedimento percutâneo estaria dentro de um limiar aceitável 
da RCEI para possível incorporação.
DESCRITORES: Permeabilidade do canal arterial. Cardiopatias 
congênitas. Cirurgia. Próteses e implantes. Análise custo-benefício.
T he ductus arteriosus is a structure present and indispensable during intrauterine life, carrying 55 to 60% of fetal cardiac output.1 After birth, a 
variety of mechanisms promote its occlusion, which 
usually is complete within 2 to 3 weeks of age.1 After 
this period, the persistence of blood flow in the chan-
nel corresponds to 7 to 11% of all congenital heart 
defects, and can be found alone or associated with other 
complex cardiac diseases.2 This incidence increases with 
prematurity, reaching 80% in those neonates weighing 
less than 1,200 g.1
Patent ductus arteriosus (PDA) persistence generates 
a picture of pulmonary over-circulation dependent on 
certain factors, including the diameter and length of 
the ductus arteriosus, and differences in pressure and 
resistance between the aorta and the pulmonary trunk.1 
In prematurity, an exacerbated pulmonary blood flow 
is not well tolerated, and early treatment becomes a 
necessity. In term newborns, the evolution depends 
greatly on the size of the ductus arteriosus, and is 
generally more benign. 
Excessive pulmonary blood flow can result in con-
gestive heart failure with low weight gain and repeated 
respiratory infections. Later, this problem can cause 
changes in distal pulmonary capillary vasculature, evolving 
to presentations of fixed pulmonary arterial hyperten-
sion.1,2 Other complications, such as infections in the 
ductus arteriosus (endarteritis) are rare events (1:13,500 
in children and 1:3,300 in adults) with declining rates, 
mainly due to early diagnosis and treatment.2
Clinical examination with auscultation of the 
heart murmur is the first step in the diagnosis, which 
is complemented by color Doppler echocardiography. 
The visualization of a flow through the ductus arterio-
sus and the hemodynamic repercussions of the defect, 
manifested by an increase of the left cardiac chambers, 
suggest the need for occlusion.
The treatment of PDA should be individualized, 
according to patient age. In premature infants, neo-
nates, and infants with up to 5 kg, surgical treatment 
is usually the choice. Percutaneous occlusion in these 
patients, although feasible, is associated with higher risks 
of failure and complications, such as left pulmonary 
artery stenosis and pseudo-coarctation.3,4 In children 
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percutaneous repair), and types of desired studies. A 
preliminary search showed that randomized clinical 
trials comparing percutaneous and surgical treatment 
in this disease have not been conducted. Thus, it was 
decided to include, in the search strategy, terms which 
also addressed to observational studies. A limitation to 
articles with abstracts that had been published in the 
previous 20 years was established with respect to the 
time of the search, which was performed on September 
9th, 2011. For Cochrane Central, the strategy included 
only aspects related to diseases and therapeutic pos-
sibilities, considering that this database contains only 
clinical trials, and thus search terms relating to outlines 
were not necessary.
Study eligibility criteria 
Studies evaluating the percutaneous or surgical 
closure of PDA in children and adolescents were in-
cluded. The prostheses used in percutaneous procedures 
should necessarily be of the coil type (Gianturco) or the 
Amplatzer Duct Occluder® (ADO – St. Jude Medical). 
The choice for these types of prostheses was rooted 
in the fact that both were approved by Federal and 
Drug Administration (FDA); are in common use in the 
pediatric interventional practice; and have extensive 
safety and efficacy, documented in the literature. Studies 
related to occlusion of PDA with coils were not used 
for economic analysis, since these devices are already 
covered by the SUS. The surgical procedure should 
have been performed by conventional technique, i.e. 
excluding procedures such as thoracoscopy or other that 
are not part of the SUS routine for treatment of PDA. 
Exclusion criteria were: studies with fewer than 
50 patients; mean (or median) age of patients > 14 
years old; mean patient weight <  6 kg; data without 
division by type of prosthesis (e.g., pooled data from 
Gianturco coils and ADO prostheses); and patient in-
clusion prior to 1991.
Process of selection of studies
Titles and abstracts of citations returned by the search 
strategy were evaluated by two reviewers. Studies that 
met the eligibility criteria or whose titles or abstracts 
did not allow a proper assessment of inclusion and 
exclusion criteria were selected for evaluation of their 
full texts. This procedure was also performed by two 
reviewers. Data from the included studies was extracted 
and entered into electronic spreadsheets.
Outcomes of interest 
The following were considered as outcomes of 
interest: perioperative and overall (within one year) 
mortality; proportion of patients who required a second 
procedure (the same or another procedure, e.g., patients 
undergoing percutaneous treatment, later requiring sur-
gery); and proportion of patients with late residual flow, 
encompassing patients who at no time were treated (e.g., 
failure of prosthesis implantation) or who were treated 
without full closure of the defect, and who remained 
so during follow-up. The number of patients with major 
complications, defined by the authors of each analyzed 
paper, including (but not limited to) those described 
in previous studies, was also considered.5 Finally, the 
mean hospitalization time was computed. 
For late residual flow outcomes, only those of 
moderate to severe grade were considered, accord-
ing to the authors’ classification; studies that did not 
report late flow intensity were considered as having 
such information missing. If the article did not report, 
during follow-up, the conduct adopted for patients with 
prosthesis implant failure after percutaneous treatment, 
it was assumed that they underwent subsequent surgical 
correction, with procedure effectiveness similar to that 
of patients with surgery as their first therapeutic choice.
Data analysis
The main purpose of this systematic review was 
the gathering of parameters for the cost-effectiveness 
model (and not for a safety and efficacy evaluation 
meta-analysis). To the extent that much of this informa-
tion was entered into the model as probabilities (and 
not as relative risks), it was decided to analyze the 
data relating to the outcomes of interest separately for 
the different strategies –surgical and percutaneous. The 
proposed initial approach was a single-arm meta-analysis 
(i.e., a meta-analysis for single groups).10 However, the 
mathematical formula in this approach cannot be used 
when no events occur, which was observed in several 
studies, considering the analyzed outcomes. 
In such cases, a possible procedure is to add 0.5 
to the number of events and to the total number of 
patients; however, this strategy is not sufficiently ac-
curate in cases with a very large rate of studies with 
zero events (> 20%), because there is an overestimate 
of the rate of occurrence of events. In such cases, the 
extraction of a weighted average is suggested, in order 
to obtain the average incidence of events in the studies 
– a procedure that was adopted in the present work.11
Economic analysis – model description 
A decision-making model was constructed to 
estimate the life expectancy and the cumulative costs 
of strategies for surgical and percutaneous closure of 
patent ductus arteriosus in the perspective of the SUS. 
The model compared the costs and benefits over the 
long-term (for life) of the two therapeutic strategies for 
closure of PDA in pediatric patients, defined as ≤  14 
years old. The first strategy consisted of surgical closure, 
by ligature or section, through lateral (classical or extra 
pleural) thoracotomy; this treatment is currently funded 
by the SUS. The second strategy consisted of percuta-
neous closure of PDA using the ADO prosthesis. The 
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analysis considered only cases with favorable diameter 
and anatomy for closing with plug-type prostheses.6 This 
restriction assumed that PDAs with diameter < 2.5 mm 
are treated with Gianturco coils, which are reimbursed 
by the SUS. A schematic representation of the model 
is shown in Figure 1.
In the surgical treatment strategy, all patients initially 
underwent PDA correction by ligation or section of the 
ductus arteriosus. The mortality rate associated to the 
procedure was analyzed. The immediate success was 
considered as a complete closure or presence of minimal 
residual shunt, as reported in the long-term follow-up 
(6 to 12 months) of reviewed literature. Patients with 
significant residual shunt (with hemodynamic repercus-
sions) after a first operation could undergo a second 
surgery or a percutaneous intervention. Additionally, in 
the model, the possibility of surgical treatment failure 
was considered, defined as the late (6 to 12 months 
after surgery) presence of a persistent shunt which had 
not been corrected for any clinical reason, or whose 
subsequent closing attempts also have resulted in failure.
In the percutaneous intervention strategy with the 
ADO prosthesis, all patients were initially treated by 
this method. The mortality associated with the method 
was analyzed. The definition for immediate success was 
the same as that adopted for the surgical strategy. Those 
patients in whom closure of PDA was not observed after 
a first intervention were eligible for a second percu-
taneous procedure, for closure of the defect (usually 
with implantation of a new device). Alternatively, the 
second intervention could consist of surgical treatment. 
For purposes of the model, it was assumed that all 
patients undergoing re-intervention of any kind would 
achieve therapeutic success, although the probabilities 
of failure of a second intervention had been considered 
in those general probabilities derived from the literature 
and used in the analysis. Those lesions that remained 
with a permanent residual flow were also computed.
Definition of base-case and estimates of survival
For the model of decision analysis to be represen-
tative of the medical practice, regarding the treatment 
of PDA in children, the present analysis defined 6 
years old as the median age of intervention. The life 
expectancy for individuals who have reached the age 
of 6 years was obtained from the general Mortality 
Table for the Brazilian population in 2010, organized 
by the Instituto Brasileiro de Geografia e Estatística 
Figure 1 – Schematic representation of the decision-making model for correction of patent ductus arteriosus (PDA).
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(IBGE); the life expectancy for individuals with PDA 
remaining uncorrected for life was derived from the 
cited table, and from those mortality estimates by age 
group of patients with PDA described by Campbell.12 
The analyzes considered only adjusted values, applying 
a discount rate of 5% per year in the estimates of life 
expectancy, according to the guidelines of the Brazilian 
Ministry of Health.13
The estimate of the long-term survival expectancy 
was performed with the adoption of the following as-
sumptions: the survival of patients with untreated PDA 
is significantly lower than that of patients with success-
fully treated PDA; the life expectancy of patients with 
successfully treated PDA is equal to that of the general 
population; this life expectancy is earned, regardless 
of the method employed for PDA closure, whether by 
percutaneous intervention or surgical treatment, provided 
there is no hemodynamically significant residual defect; 
the current life expectancies for different age groups, 
calculated from the Mortality Table by IBGE, 2010, 
represent the life expectancy in the absence of PDA, 
considering the very low incidence of this condition 
(0.006-0.047%) and that virtually all diagnosed cases 
are currently treated; the only explanation for a differ-
ence in survival of patients with PDA percutaneously 
or surgically treated would come from the different 
rates of immediate success in the defect closure with 
one of the methods.
Mortality Table and extrapolation to individuals 
with patent ductus arteriosus 
As already detailed, to calculate the expected sur-
vival for patients with PDA (uncorrected, or with late 
residual shunt with hemodynamic repercussions), this 
analysis used the estimate from the Mortality Table by 
IBGE in 2010. In that year, the life expectancy for an 
individual in the general population who had reached 
the age of 6 years was 69.5 years.
In order to obtain a comparable estimate of the 
life expectancy of patients with uncorrected PDA ver-
sus that of the general population, a mortality table 
based on the integration among the estimates from 
the literature and the mortality table of the Brazilian 
population was projected. The method used was an 
adaptation of that described by Pharoah and Hol-
lingworth.14 Briefly, the method consists in calculating 
the fraction of mortality by age group attributable to 
a particular health condition. In the present study, the 
adaptation consisted in assume that, for the Brazilian 
population, the current mortality rate of the general 
population by age group is not significantly influenced 
by the presence of untreated PDA in the population, 
taking in consideration: (a) the low estimated prevalence 
for this condition, and (b) the fact that virtually all 
diagnosed cases of PDA with hemodynamic repercus-
sion are currently treated in Brazil.
Costs
The costs were obtained from SUS reimbursement 
values in 2010, related to the procedures of surgical 
closure of PDA (R$ 8,432.00) and cardiac catheterization 
(R$  800.00 – diagnostic hemodynamic study, without 
the costs of covered devices, in the case of Gianturco 
coils). The ADO prosthesis was used in the base-case 
of the analysis because this device is not covered by 
SUS, and also due to the extensive experience, safety, 
and efficacy of this device, documented in various 
case series.4 The cost of the ADO prosthesis used in 
the analysis was set at R$ 10,000.00, with R$ 8,000.00 
for the prosthesis and R$ 2,000.00 for the releasing 
system. These values correspond to those used in a 
study that evaluated the safety and efficacy of both 
treatment methods, conducted in one of the Brazilian 
Ministry of Health charity hospitals of excellence and 
funded by this Ministry as part of a project to assess 
new technologies.5
Considering that all costs included in the analysis 
fall within the present time (i.e., at the time of interven-
tion), and that the long-term costs appear to be similar 
among patients treated with surgery or by percutaneous 
intervention, neither adjustment of costs was performed 
for inflation or discount rates, nor indirect costs related 
to procedures, such as expenses with the blood bank 
(serology and other pre-transfusional examinations), and 
loss of workdays by parents or guardians were included. 
The model was developed with the program Tree-
Age, version 9.12. Sensitivity analyzes were conducted, 
considering alternative parameters of effectiveness, pros-
thesis costs, probability of success, and procedure-related 
death. Thresholds were estimated (threshold analyzes) 
to determine whether the new technology evaluated, 
from the perspective of the SUS (percutaneous closure of 
PDA with ADO prosthesis), was cost-effective. To allow 
a better interpretation, a willingness to pay a threshold 
value of R$ 57,000.00 (three times the per capita Gross 
Domestic Product [GDP] in 2010) per QALY (quality-
adjusted life year, i.e., quality of life adjusted for year 
of life gained). This study was not intended to perform 
a deeper statistical approach; however, in general, the 
concept of QALY relates to an increase in quality of 
life and survival time, through incorporation of a new 
procedure or a different treatment.15
RESULTS
Systematic review
After reviewing titles and abstracts of articles found 
by the systematic review, 77 papers remained and were 
analyzed in full text. Thirty-three were excluded: 11 for 
having fewer than 50 patients; seven due to studying 
prostheses or surgeries different from those defined in 
the eligibility criteria; 5 for presenting data not sepa-
rated by type of procedure or prosthesis; 3 representing 
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re-analyses of data already published; 2 for including 
patients prior to 1991; 2 for including patients with 
a mean weight <  6 kg; 1 for including patients with 
a mean age >  14 years old; 1 for not presenting any 
outcome of interest; and one for data judged to be 
unreliable, since the study showed a subset of pooled 
cases with poorly defined selection criteria. 
Of the 44 articles included (Table 1 and Appendix 
1), nine had more than one group of patients. Twenty-
seven articles were related to occlusion procedures 
with coils, and 22 used almost 100% Gianturco coils. 
Thus, for the economic data analysis, 9 articles 
with surgical data and 17 articles with data from the 
ADO prosthesis were included.
Surgical closure
A total of 9 articles were selected, with a total 
of 1,254 patients analyzed. The patients’ final year of 
inclusion ranged from 1993 to 2007. The mean age 
of these patients was 5.1 years. The follow-up period 
ranged from four months to 6 years. The average size 
of PDA was between 1.5 and 4.0 mm in two studies 
and  >  5 mm in three other studies; the other articles 
did not report this information.
Death
Eight studies included the perioperative death 
outcome, with a total of 1,213 patients. The weighted 
average obtained across these studies for this outcome 
was 0.08%. Ten studies reported overall deaths, with 
n = 1,319. The weighted average obtained was 0.22% 
(Figure 2). 
Need for a second procedure 
Eight studies that provided data for requiring a second 
surgery, with a total of 1,213 patients evaluated, were 
included. On average, 0.57% of patients underwent a 
second surgical intervention. Importantly, these corrections 
were performed in another hospitalization, mostly for a 
later correction of residual shunts. As to the outcome of 
performing a percutaneous closure after surgical failure, the 
same eight studies were included. The weighted average 
obtained was 0.32%. The data relating to the need for a 
second procedure are shown in Figure 3.
Residual flow and other complications
Of those studies included, five had a complete 
dataset for the evaluation of moderate or large late 
residual shunts, with a total of 725 patients. The 
weighted average observed was 0.41% (Figure 4). It is 
important to keep in mind that this value reflects the 
number of patients who persisted with a shunt at the 
end of follow-up, i.e., after excluding patients who had 
their defects corrected by a possible second procedure. 
Another relevant detail is that four of these studies had 
ligation as their surgical technique; the fifth combined 
this technique (i.e., ligation) with section (but without 
rate improvement versus other studies, which was 0.6%).
As to the outcome of major complications, four 
studies were included, with a total of 475 patients. The 
remaining studies had no clear data for this outcome, 
quite often mixing data regarding minor complications. 
The weighted average of major complications was 
11.36% (Figure 5).
Average in-hospital length of stay 
Only four studies reported mean hospitalization 
time, with a total of 548 patients. Three of them showed 
values between 8 and 9 days, and the last study had 
an average of 3.6 days. The weighted average of these 
studies was 7.01 days (Figure 6).
Percutaneous intervention with the Amplatzer 
Duct Occluder® 
Seventeen articles studying the ADO prosthesis were 
included, with a total of 1,705 patients. The final year 
of inclusion of patients in the articles ranged between 
1999 and 2009. The mean age of these patients was 
4.8 years. The mean size of PDA ranged between 2.0 
and 6.5 mm. The follow-up period ranged from a few 
days up to five years.
Death
Thirteen studies (n = 1,465) reported mortality data, 
with only one perioperative death. Thus, the proportion 
of perioperative and overall death was equal, equivalent 
to 0.06% (Figure 2).
Need for a second procedure 
Thirteen studies (n = 1,368) reported data on need 
for a surgical procedure due to incomplete closure of 
the defect, or by embolization. The weighted average 
for occurrence of this event was 1.46% (Figure 3). 
Conversely, 12 studies reported the necessity of a new 
hemodynamic procedure (n = 1,216). On average, this 
outcome occurred in 0.82% of patients.
Residual flow and other complications
Eight studies (n = 553) were included in the 
evaluation of the residual shunt outcome, with a mean 
incidence of 0.18% (Figure 4). With regard to other 
complications, seven studies reported outcomes ap-
propriately (n = 514), with a mean estimated incidence 
of 2.52% (Figure 5).
Mean in-hospital lengthof stay
Only three studies reported data on mean in-hospital 
length of stay, with a total of 188 patients. The weighted 
average obtained was 1.73 day (Figure 6).
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TABLE 1 
Key data of studies included in the cost-effectiveness analysis after applying the exclusion criteria (Appendix 1)
Author Year Journal Prosthesis or surgery
Age  
(years)
Surgeries 
(n)
Prostheses  
(n)
Mavroudis et al.1 1994 Ann Surg. Ligation and section 3.6 175
Rosenthal et al.2 1996 Heart. Coil (various 
manufacturers)
3.7 57
Shim et al.3 1996 J Am Coll Cardiol. Gianturco Coil 3.5 75
Hjiazi et al.4 1997 Am J Cardiol. Gianturco Coil 2.1 100
Pedra et al.5 1998 Arq Bras Cardiol. Gianturco Coil 5.4 87
Janorkar et al.6 1999 Am Heart J. Gianturco Coil 7.0 60
Goyal et al.7 1999 Am J Cardiol. Gianturco Coil 4.0 84
Raaijmaakers et al.8 1999 Cardiol Young. Ligation - 100
Patel et al.9 1999 Catheter Cardiovasc Interv. Gianturco Coil 2.4 149
Ing et al.10 1999 J Am Coll Cardiol. Gianturco Coil 3.3 104
Hwang et al.11 2000 Angiology. Coil/ligation 5.6 9 105
Faella et al.12 2000 Catheter Cardiovasc Interv. ADO 2.1 316
Shrivastava et al.13 2000 Indian Pediatr. ADO/Coil 6.9/6.5 44/48
LeBlanc et al.14 2000 Int Surg. Ligation 1.1 231
Galal et al.15 2001 Eur Heart J. Gianturco Coil 4.7 135
Thanopoulos et al.16 2001 J Interv Cardiol. ADO 6.5 69
Bilkis et al.17 2001 J Am Coll Cardiol. ADO 1.9 209
Turner et al.18 2002 Am Heart J. Gianturco Coil 2.4 94
Laohaprasitiporn et al.19 2002 J Med Assoc Thai. Gianturco Coil 6.5 77
Liang et al.20 2003 Am Heart J. Gianturco Coil 5.5 75
Jacobs et al.21 2003 Ann Thorac Surg. Gianturco Coil 4.6 99
Fu et al.22 2003 Jpn Heart J. Gianturco Coil 2.9 154
Kumar et al.23 2004 Catheter Cardiovasc Interv. Gianturco Coil 0.7 41 86
Masura et al.24 2006 Am Heart J. ADO 3.4 64
Wang et al.25 2006 Int J Cardiol. Coils 7.8 317
Lee et al.26 2006 J Formos Med Assoc. Gianturco Coil 2.9 52
Vanamo et al.27 2006 J Pediatr Surg. Ligation 1.0 60
Demir et al.28 2007 Cardiol Young. Ligation and section 5.5 325
Atiq et al.29 2007 J Invasive Cardiol. ADO 7.0 52
Gudausky et al.30 2008 Catheter Cardiovasc Interv. Gianturco Coil 5.5 64
Kramoh et al.31 2008 Pediatr Cardiol. Gianturco Coil 4.6 NA 139
Chen et al.32 2009 Chin Med J. ADO/ligation 10.2 183 72
Huang et al.33 2009 Circ J. ADO/Gianturco Coil 4.4/9.1 55/21
Shabbir et al.34 2009 J Coll Physician Surg Pak. ADO 11.7 100
Lertsapcharoen et al.35 2009 J Invasive Cardiol. ADO 4.0 60
Gowda et al.36 2009 Pediatr Cardiol. Gianturco Coil 3.5 128
Chen et al.37 2009 Pediatr Cardiol. ADO/ligation 13.3 130 51
Xie et al.38 2009 World J Pediatr. Gianturco Coil 3.4 126
Thanopoulos et al.39 2010 Am J Cardiol. ADO 3.6 65
Willcoxson et al.40 2010 Cardiol Young. ADO - 101
Brunetti et al.41 2010 Catheter Cardiovasc Interv. ADO/Gianturco Coil 4.3 174/161
Ghasemi et al.42 2010 Catheter Cardiovasc Interv. ADO/Gianturco Coil 6.8/4.7 152/120
Kharouf et al.43 2011 Catheter Cardiovasc Interv. ADO 1.8 70
Bajic et al.44 2011 Catheter Cardiovasc Interv. ADO 2.6 51
ADO: Amplatzer® Duct Occluder; NA: not available.
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Economic analysis
Base-case: model using estimates of the systematic 
literature review 
Considering the costs incurred in the sequence of 
events and all possible outcomes (closure, complications, 
and re-interventions), an incremental cost-effectiveness 
ratio (ICER) of R$ 71,380.00 was found per year of life 
gained for the percutaneous closure of PDA with the 
ADO prosthesis. This value was obtained in the main 
analysis, with life expectancies discounted at 5% per 
year, a value higher than the limit value for an inter-
vention to be considered cost-effective – R$ 57,000.00 
per year of life gained, corresponding to three times 
the value of Brazilian GDP per capita in 2010 (R$ 
19,016.00). Data relative to ICER are shown in Table 2.
Sensitivity analysis 
From the base-case derived of literature data and 
including a discount rate of 5% in the evaluation of 
effectiveness, a threshold analysis was conducted to 
determine the maximum limit-cost, so the use of the 
ADO prosthesis achieved an ICER of up to R$ 57,048.00/
year of life. In these terms, the ADO prosthesis would 
present an ICER considered acceptable for reimbursement 
at a maximum cost of R$ 9,507.00, including the cost 
of the delivery system. On the basis of this value, from 
an economic standpoint the surgical treatment would 
be the most attractive option. Figure 7 summarizes the 
threshold analysis and shows the expected variation of 
ICER for variations in the cost of the ADO prosthesis 
between R$ 4,000.00 and R$ 16,000.00.
Figure 2 – Peri-operative and overall mortality of surgical and percu-
taneous procedures for closure of patent ductus arteriosus.
Figure 6 – Total hospitalization time for surgical and percutaneous 
procedures for closure of patent ductus arteriosus.
Figure 5 – Major complications of surgical and percutaneous procedures 
for closure of patent ductus arteriosus complications.
Figure 4 – Moderate-to-large residual blood flow shunt after surgical 
and percutaneous procedures for closure of patent ductus arteriosus.
Figure 3 – Need for surgical re-intervention after surgical and percu-
taneous procedures for closure of patent ductus arteriosus.
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DISCUSSION
PDA is one of the most common congenital heart 
diseases, and its timely treatment leads to patient’s 
healing and to a life expectancy equal to that of the 
general population. From 1990 onwards, there has been 
a marked progress in the techniques of percutaneous 
closure of this lesion. Today, this procedure is one of 
the most frequently performed in the catheterization 
laboratories of large referral centers. However, there 
are still few the studies comparing the results of this 
method with the surgical approach. 
This study sought to identify the evidence on the 
safety and efficacy of both treatment options, and to 
perform an analysis of incremental cost-effectiveness 
as a basis for possible incorporation of the technology 
(PDA closure with plug-type prosthesis) by the SUS. The 
extensive literature review conducted here showed that 
the efficacy data of both treatment strategies are based 
on observational studies and uncontrolled experiments, 
with no direct comparison in randomized trials. Consid-
ering that the percutaneous treatment has already been 
adopted as procedure of choice in children weighing 
> 6 kg in major world centers, it is unlikely that both 
strategies will be compared in future randomized clini-
cal trials. Thus, the available evidence for an evaluation 
will not increase in quality in the future.
To the authors’ knowledge, in the Brazilian literature 
there are no published studies comparing the costs of 
both treatment methods (surgical vs. percutaneous) of 
PDA, whether from the perspective of public health or 
within the realm of supplementary health. This is not 
only a pioneering study in this direction, but also in its 
economic analysis. The authors evaluated the incremental 
cost-effectiveness (during life) of both treatment strate-
gies, which is crucial for the incorporation of a new 
technology in the public health system. The Brazilian 
Ministry of Health itself mandates the conduction of 
this type of economic analysis.13
This study is based on a systematic literature review 
with analysis of the main possible outcomes in both 
treatment strategies, for creating a decision-making 
model similar to that observed in daily clinical practice. 
The model generated showed an adjusted cumulative 
effectiveness estimate (lifelong survival) very similar 
between the two therapies, with slightly higher benefit 
for percutaneous therapy with the ADO prosthesis. How-
ever, the incremental cost-effectiveness ratio with the 
use of ADO was rather high, at about R$ 71,000.00 per 
year of life saved. In the threshold analysis performed, 
it was perceived that a small reduction in the cost of 
the device (approximately R$ 500.00) would bring this 
ratio to an acceptable value, R$ 57,000.00 per year 
of life saved, corresponding to three times the value 
of Brazilian GDP per capita in 2010 (R$ 19,016.00).
Even with a slightly elevated incremental cost-
effectiveness ratio with the values stipulated in this study, 
there are several reasons for a possible incorporation 
of this technology by the SUS. First, it is important to 
understand the context in which the ADO prosthesis 
would be used in the context of the SUS, so that its 
indication would be individualized, and with conse-
quent impact on cost reduction. This study considered 
that all patients with PDA would be treated with the 
ADO prosthesis, and this is not really necessary in 
clinical practice. According to a study from Toronto, 
with respect to the ductus arteriosus, about one-third 
measure < 2.5 mm at the angiography, and almost 90% 
of these defects exhibit an A-, D-, or E-type constriction 
on the pulmonary side.6 In patients exhibiting channels 
TABLE 2 
Cost-effectiveness and incremental cost-effectiveness ratio (ICER)  
of surgical and percutaneous treatment strategies for patent ductus arteriosus
Cost (R$)
Effectiveness –with discount 
(years of life gained)
ICER–with 
discount (R$)
Surgical treatment 8,507.00 19.71 –
Percutaneous treatment (Amplatzer Duct 
Occluder®)
11,000.00 19.74 R$ 71,380.00
Figure 7 – Threshold analysis. Effect of variation in the cost of Amplatzer 
Duct Occluder® (ADO) prosthesis, including delivery system, in the 
incremental cost-effectiveness ratio (ICER), compared to surgical treatment.
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with these types and sizes, the use of Gianturco coils, 
which are devices already covered by SUS, is very 
safe and results in high rates of occlusion, as seen 
in experiments in this scenario.10 These patients may 
still be treated with the use of springs, with an excel-
lent incremental cost-effectiveness ratio, considering 
that, today, the SUS pays R$ 1,953.00 for this device, 
including its release system. Such individualization 
of strategies, according to the basic anatomy of the 
patient, would optimize the overall cost-effectiveness 
ratio of percutaneous closure of PDA, and would bring 
this result to an acceptable threshold for incorporating 
the ADO prosthesis in the SUS.
It is acknowledged that the type and size distribu-
tion of arterial channels observed in Toronto may not be 
the same as in Brazil. However, most Brazilian centers 
performing percutaneous closure of PDA are situated 
in areas with similar geographical characteristics to 
those of Ontario, Canada, where the mentioned study 
was conducted. Considering that Brazil does not have 
a significant portion of the population living at high 
altitudes, is unlikely to find a high prevalence of no-
constriction, large-diameter channels, as observed in 
Mexico City and La Paz, Bolivia.16
Additionally, it is noteworthy to that the present 
cost analysis took into account only the direct costs 
related to the procedures, such as using the hemo-
dynamics laboratory, surgical center, materials and 
supplies, and medical and support team expenses. 
These items are the easiest to measure. Conversely, 
indirect costs, which are more difficult to estimate, 
were not accounted for in this study. While acknow-
ledging the speculative nature of this observation, it 
is believed that if such values had been considered, 
the incremental cost-effectiveness ratio would be much 
higher for the surgical treatment. As it is known, the 
surgery for patent ductus arteriosus requires greater 
use of blood products,5 with a consequent increase in 
costs related to the use of the blood bank (collection 
and distribution of bags, serology and blood typing, 
among others).
Although this study was not designed to perform 
a comparison of clinical outcomes in relation to the 
safety and efficacy of each therapeutic method studied, 
the systematic review of the literature performed here 
corroborated observations previously found in the lit-
erature, showing that the percutaneous closure of PDA 
has similar efficacy, in addition of lower complication 
rates and shorter hospitalization time, when compared 
to the surgical procedure. These observations are con-
sistent with findings from the clinical study performed 
at this institution and funded by the Brazilian Ministry 
of Heal thin order to compare the safety and efficacy of 
both treatment methods for PDA.5 It is probable that the 
greater morbidity (mainly by infectious and respiratory 
complications) and the hospitalization time of the surgical 
treatment of PDA would result in greater indirect costs. 
In addition, the longer hospitalization time hinders the 
rapid return of patients to their routine activities, with 
possible work losses for parents or guardians. Indirect 
costs of these potential losses are difficult to quantify. 
It is also noteworthy that the longer hospitalization 
time required to treat this relatively simple congenital 
heart disease hinders the rapid turnover of beds in 
centers performing surgeries for more complex heart 
diseases, reducing the capacity and effectiveness of 
the hospital system, especially if it is considered that 
there is a repressed demand for the surgical treatment 
of congenital heart diseases.17
Even though a willingness-to-pay threshold of R$ 
57,000.00 was used (three times the per capita Brazilian 
GDP in 2010) per QALY in this study, other methods 
for determining thresholds are used in other (usually 
developed) countries, which take into account a fixed 
value of US$ 50,000.00.18 If this criterion had been 
used, the closure of PDA with the ADO prosthesis 
would have been cost-effective from the incremental 
point of view, and amenable to incorporation. 
This study has some limitations. The absence of 
a threshold analysis related to quality of life and loss 
of workdays by parents or guardians is one limitation. 
Although the effect of severe complications in mor-
tality rates and the chances of re-intervention were 
contemplated in this analysis, the impact on quality 
of life and on school- and employment-absences was 
not evaluated. The procedure of thoracotomy and the 
pain due to the incision probably reduced the qual-
ity of life of patients in the first month after surgery, 
further delaying the return to routine activities. In view 
of this, parents or guardians reduce their workload to 
care for the patient, indirectly incurring in a burden on 
society. In this study, the SUS table currently available 
for reimbursement of cardiac catheterization for closure 
of PDA was used. The authors recognize the need to 
update this table, both for reimbursement in order to 
cover hospital expenses such as doctors’ fees, as well 
as for medical fees. Such an update would increase the 
incremental cost-effectiveness of percutaneous closure. 
The outcome analysis was performed considering the 
use of the ADO prosthesis, which has its safety and 
effectiveness widely documented in the literature and 
in clinical practice. Although other plug-type nitinol 
prostheses from other brands and manufacturers are 
available in the Brazilian market, the literature relevant 
to these devices is still scarce. Currently, it cannot be 
stated with certainty that the use of other devices would 
result in clinical outcomes similar to those observed 
with the ADO prosthesis. 
This study can be considered as a first step in a 
series of actions for the possible incorporation of this 
technology by the SUS. A study of incremental cost-
effectiveness similar to the present, but more accurate 
and appropriate to the contemporaneous reality, should 
take into account the following aspects: about one-third 
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of patients with PDA can be treated with Gianturco coils; 
the reimbursement values of cardiac catheterization (in-
cluding medical fees) must be updated; and the indirect 
costs should be accounted for. The authors believe that 
such a study is feasible, for subsequent calculation of 
the impact on the Brazilian budget, and for a definitive 
incorporation of this technology. Considering that the 
prevalence of cases of patent ductus arteriosus in the 
general population is very low, it can be speculated 
that such impact would be limited.
CONCLUSIONS
The percutaneous treatment of patent ductus 
arteriosus with the ADO prosthesis presented lower 
morbidity and shorter in-hospital length of stay, and 
an effectiveness similar to that of surgical treatment. 
With the direct values  stipulated in this study and 
assuming that the entire population of patients with 
patent ductus arteriosus would be treated with the 
ADO, the procedure of percutaneous closure had 
lower incremental cost-effectiveness. However, with a 
small reduction in values for the kit of materials, the 
percutaneous procedure would be within an accept-
able threshold of incremental cost-effectiveness ratio 
for possible incorporation by the SUS.
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